

# Changes in Waist Circumference and Body Mass Index in Relation to Changes in Serum Uric Acid in Japanese Individuals

NOBUKAZU ISHIZAKA, YUKO ISHIZAKA, AKIKO TODA, MIZUKI TANI, KAZUHIKO KOIKE, MINORU YAMAKADO, and RYOZO NAGAI

**ABSTRACT.** *Objective.* Studies have shown that obesity is associated with an increase in serum uric acid; and few data are available on the relationship between changes in measures of obesity and changes in uric acid concentrations. We investigated the relationship among percentage changes in waist circumference (%dWC), body mass index (%dBMI), and serum uric acid (%dUA).

*Methods.* The data of 3153 individuals [1968 men, 1185 women (536 premenopausal, 649 postmenopausal)] who underwent general health screening over a 2-year period and were not taking anti-hyperuricemic medication were analyzed.

*Results.* Stepwise multiple regression analysis showed that %dBMI was associated positively with %dUA in postmenopausal women and men, and the association retained statistical significance after adjustment for changes in blood pressure and in renal function. Association between %dBMI and %dUA was not significant in premenopausal women. In men, %dWC was a predicting factor for %dUA, although it did not remain significant when %dBMI was used as a covariate in the statistical model. Multivariate logistic regression analysis showed that the odds ratio of the association between the lowest %dBMI quartile (%dBMI < -1.86) and the lowest %dUA quartile (%dUA < -7.41) was 2.04 (95% CI 1.35–3.07) in postmenopausal women and 1.46 (95% CI 1.14–1.86) in men.

*Conclusion.* Weight loss may represent an effective nonmedical strategy for reducing serum UA levels, especially in postmenopausal women and men. (J Rheumatol First Release Dec 23 2009; doi:10.3899/jrheum.090736)

## Key Indexing Terms:

WAIST CIRCUMFERENCE  
GLOMERULAR FILTRATION RATE

BODY MASS INDEX

URIC ACID  
BLOOD PRESSURE

Obesity and serum uric acid (UA) are both associated with enhanced insulin resistance and incidence of metabolic syndrome<sup>1-3</sup>. In addition, measures of obesity have been reported to be positively associated with serum levels of UA<sup>4,5</sup>, an association that may be caused by impaired renal clearance

of UA in the condition of obesity<sup>6</sup>. The finding that a reduction in weight, and thus in body mass index (BMI), may have a significant effect on serum UA<sup>7</sup> and renal urate excretion<sup>6</sup> suggests that changes in weight may play a role in the regulation of serum UA levels, although the reverse scenario might also be possible<sup>8</sup>. In our study, by analyzing individuals who underwent general health screening, we examined the influence of changes in waist circumference (WC) and BMI on changes in UA, and the dependency/independency on changes in either blood pressure or renal function, which is the possible critical factor affecting serum UA levels in healthy subjects<sup>9</sup>.

## MATERIALS AND METHODS

*Study population.* The study was approved by The Ethical Committee of Mitsui Memorial Hospital. Between October 2005 and October 2006, 11,558 individuals underwent general health screening at our institute. Of these, 3326 individuals (2113 men, 1213 women) underwent general health screening during this period (first visit) and again the following year (second visit). Among these 3326 individuals, 3179 (1968 men, 1211 women) reported taking no antihyperuricemic drugs at either visit. Among the 1211 women, 1185 (98%) answered the questionnaire concerning whether they still had menstruation, and were enrolled for study. Therefore, we analyzed data of 3153 individuals (1968 men, 1185 women). The mean  $\pm$  standard deviation (SD) interval between the 2 visits of the individuals enrolled was

---

From the Department of Cardiovascular Medicine and Department of Gastroenterology, University of Tokyo Graduate School of Medicine, Tokyo; and Center for Multiphasic Health Testing and Services, Mitsui Memorial Hospital, Tokyo, Japan.

Supported in part by a grant from Chiyoda Mutual Life Foundation, and by the St. Luke's Grant for the Epidemiological Research, Daiwa Securities Health Foundation, Gerontology Research Grant of Kowa Life Science Foundation, Foundation for Total Health Promotion, Gout Research Foundation of Japan, Kurozumi Medical Foundation, and a Grant-in-Aid from the Ministry of Health, Labour, and Welfare, Japan.

N. Ishizaka, MD, Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine; Y. Ishizaka, MD; A. Toda, MD; M. Tani, MD, Center for Multiphasic Health Testing and Services, Mitsui Memorial Hospital; K. Koike, MD, Department of Gastroenterology, University of Tokyo Graduate School of Medicine; M. Yamakado, MD, Center for Multiphasic Health Testing and Services, Mitsui Memorial Hospital; R. Nagai, MD, Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine.

Address correspondence to Dr. N. Ishizaka, Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Hongo 7-3-1 Bunkyo-ku, Tokyo 113-8655, Japan. E-mail: nobuishizaka-iky@umin.ac.jp  
Accepted for publication September 15, 2009.

356.2 ± 51.7 days. WC, BMI, UA, systolic blood pressure, and estimated glomerular filtration rate (eGFR) at the first visit were designated WC1, BMI1, UA1, BPs1, and eGFR1, respectively, and at the second visit WC2, BMI2, UA2, BPs2, and eGFR2.

The percentage differences between values of WC1 and WC2, BMI1 and BMI2, UA1 and UA2, BPs1 and BPs2, and eGFR1 and eGFR2 were designated %dWC, %dBMI, %dUA, %dBPs, and %deGFR. All participants were seen after an overnight fast. Height and weight were determined, and BMI was expressed as weight (kilograms) divided by the square of height (meters). With the subject standing, waist circumference was measured at the umbilical level to the nearest 1 cm by trained physicians and technicians<sup>10</sup>.

**Laboratory analysis.** Blood samples were taken after an overnight fast. Serum levels of low density lipoprotein (LDL), high density lipoprotein (HDL) cholesterol, and triglycerides were determined enzymatically. Serum UA was measured by the uricase-peroxidase method, and hemoglobin A<sub>1c</sub> by latex agglutination immunoassay. Creatinine was measured by TBA-200FR (Toshiba Medical Systems, Tochigi, Japan) using a commercial kit. Accuras Auto CRE (Shino-test, Tokyo, Japan) eGFR was calculated by the equation:  $eGFR = 194 \times (\text{serum creatinine})^{-1.094} \times (\text{age})^{-0.287} (\times 0.739 \text{ if female})$ <sup>11</sup>. This equation was recently determined by a multicenter study, and differs from the equation<sup>12</sup> that we used in previous studies<sup>13-15</sup>. Blood pressure was measured after about 10 min of rest with an automated sphygmomanometer.

**Statistical analysis.** Data are expressed as the mean ± SD unless stated otherwise. Analyses of variance with trend analysis and stepwise multiple regression analysis were conducted as appropriate to assess the statistical significance of differences between groups using SPSS II (SPSS Inc., Chicago, IL, USA). A value of  $p < 0.05$  was taken to be statistically significant.

## RESULTS

**Baseline characteristics.** We enrolled 536 premenopausal women, 649 postmenopausal women, and 1968 men for study. At the first visit the mean age of premenopausal women was 43.1 ± 5.51 years, postmenopausal women 59.1 ± 6.8 years, and men 53.3 ± 10.2 years. The sex-nonspecific range of the first to the fourth %dUA quartiles (maximum/minimum) was -47.2/-7.5, -7.4/-1.2, 0.0/7.1, and 7.2/77.8 (Table 1). A plot of WC1 and BMI1 compared to UA1 is shown in Figure 1. In both men and women, there was a statistically significant correlation between WC1 or BMI1 and UA1. The correlation coefficient between WC1 and BMI1 was 0.626 ( $p < 0.001$ ) in premenopausal women, 0.563 ( $p < 0.001$ ) in postmenopausal women, and 0.838 ( $p < 0.001$ ) in men.

**Relationship between %dWC, %dBMI, and %dUA.** The relationship between %dBMI and %dUA, although very weak, was significant in postmenopausal women and men, and the relationship between %dWC and %dUA was significant only in men (Figure 2). In premenopausal women, the relationships between %dWC and %dUA and between %dBMI and %dUA were not statistically significant. The correlation coefficient between %dWC and %dBMI was 0.267 ( $p < 0.001$ ) in premenopausal women, 0.221 ( $p < 0.001$ ) in postmenopausal women, and 0.484 ( $p < 0.001$ ) in men.

We next performed stepwise multiple regression analysis

(Table 2). In a model in which age, UA1, WC1, and %dWC were used as independent variables (model 1), %dWC was found to have independent predictive value for %dUA in men, but not in women. However, after adding BMI1 and %dBMI as independent variables, %dWC in men was no longer a predictor for %dUA (model 2). %dBMI was found to be a predictor for %dUA in postmenopausal women and men even after using either or both %dBPs and %deGFR as independent variables (models 3-5). On the other hand, in premenopausal women, %dBMI was not a significant predictor value for %dUA in any of these models. In addition, in a model in which age, UA1, BMI1, and %dBMI were used as independent variables, %dBMI again was not found to have significant predictive value for %dUA (data not shown). In model 5, variance inflation factor (VIF) scores of all the independent variables were less than 10 (data not shown).

**Logistic regression analysis.** When the highest %dUA quartile ( $\%dUA \geq 7.25$ ) was used as a dependent variable, logistic regression analysis showed that the highest %dBMI quartile ( $\%dBMI \geq 1.47$ ) had a significant positive association in postmenopausal women and in men after adjusting for UA1 and BMI1 (Table 3, model 1). In these groups, statistical significance was retained even after further adjustment for %dBPs and %deGFR (model 2). On the other hand, in premenopausal women, the highest %dBMI quartile was, unexpectedly, negatively associated with the highest %dUA quartile, although statistical significance was lost after further adjustment for %dBPs and %deGFR. In all 3 subgroups tested, %deGFR was negatively associated with the highest quartile of %dUA.

Logistic regression analysis showed that the lowest %dBMI quartile ( $\%dBMI < -1.86$ ) had a significant positive association with the lowest %dUA quartile ( $\%dUA < -7.41$ ) in postmenopausal women and men, and this remained statistically significant even after further adjustment for %dBPs and %deGFR (model 2). But in premenopausal women, association between the lowest %dBMI quartile and lowest %UA was not statistically significant regardless of this further adjustment.

## DISCUSSION

Analyzing data of individuals who underwent general health screening and who were taking no antihyperuricemic medication, we found that correlation between percentage changes in BMI (%dBMI) and in UA (%dUA) was statistically significant in postmenopausal women and in men, but not in premenopausal women.

Stepwise multiple regression analysis showed that %dWC is a significant independent variable for %dUA in men, where UA1, WC1, and %dWC was used as possible independent variables (model 1); however, the relationship lost statistical significance after further adjustment for BMI1 and %dBMI (Table 3). %dWC was not found to be a

Table 1. Baseline characteristics at the first visit according to %dUA quartiles.

Variables	Total, n	% dUA Quartile				p for Trend
		First (range -47.2/-7.5)	Second (range -7.4/-1.2)	Third (range 0.0/7.1)	Fourth (range 7.2/77.8)	
Women/men	1185/1968	290/496	252/483	327/514	316/475	
Baseline data at visit 1						
Age, yrs	52.8 ± 10.2	52.6 ± 10.6	53.3 ± 10.1	52.9 ± 10.0	52.3 ± 10.2	0.225
Waist circumference, cm	82.3 ± 9.2	82.8 ± 9.6	82.7 ± 9.1	82.2 ± 8.7	81.7 ± 9.3	0.074
Body mass index, kg/m <sup>2</sup>	22.8 ± 3.1	23.0 ± 3.3	22.8 ± 3.0	22.8 ± 3.0	22.6 ± 3.1	0.056
Systolic blood pressure, mmHg	123 ± 19	124 ± 20	123 ± 19	122 ± 19	123 ± 19	0.636
LDL-cholesterol, mg/dl	129.1 ± 31.2	130.2 ± 31.3	129.4 ± 29.5	129.8 ± 31.3	126.9 ± 32.2	0.147
HDL-cholesterol, mg/dl	60.7 ± 15.3	60.7 ± 15.8	60.5 ± 15.5	60.8 ± 14.8	60.9 ± 15.1	0.980
Triglyceride, mg/dl	111 ± 72	112 ± 75	115 ± 81	109 ± 67	109 ± 65	0.249
Uric acid, mg/dl	5.5 ± 1.3	5.8 ± 1.5	5.7 ± 1.2	5.4 ± 1.3	5.1 ± 1.2	< 0.001
Fasting glucose, mg/dl	96 ± 21	97 ± 20	96 ± 19	95 ± 18	96 ± 25	0.486
Hemoglobin A1c, %	5.3 ± 0.7	5.3 ± 0.7	5.3 ± 0.7	5.3 ± 0.7	5.3 ± 0.9	0.941
Blood urea nitrogen, mg/dl	14.1 ± 3.5	14.6 ± 4.0	14.3 ± 3.2	14.1 ± 3.3	13.6 ± 3.5	< 0.001
Serum creatinine, mg/dl	0.77 ± 0.29	0.79 ± 0.42	0.78 ± 0.15	0.76 ± 0.15	0.75 ± 0.34	0.068
Estimated glomerular filtration rate, ml/min/1.73m <sup>2</sup>	68.3 ± 11.8	67.3 ± 11.8	67.8 ± 11.5	68.1 ± 11.4	70.2 ± 12.4	< 0.001
Antihypertensive medication, n (%)	306 (9.7)	78 (9.9)	78 (10.6)	76 (9.0)	74 (9.4)	0.736
Antidiabetic medication, n (%)	74 (2.3)	19 (2.4)	14 (1.9)	24 (2.9)	17 (2.1)	0.632
Postmenopause (female), n (%)	649 (54.8)	152 (52.4)	141 (56.0)	194 (59.3)	162 (51.3)	0.165
Current smoker, n (%)	734 (23.3)	180 (22.9)	173 (23.5)	197 (23.4)	184 (23.3)	0.992
Percent change between 2 visits						
%dBMI	-0.28 ± 3.1	-0.70 ± 3.41	-0.46 ± 3.06	0.01 ± 2.88	-0.03 ± 2.98	< 0.001
%dWC	0.17 ± 6.12	-0.02 ± 6.33	-0.35 ± 6.14	0.64 ± 6.14	0.35 ± 5.83	0.008
%deGFR	1.8 ± 10.0	6.3 ± 10.0	2.6 ± 9.0	0.9 ± 9.1	-2.5 ± 10.0	< 0.001

predictive value for %dUA in premenopausal or postmenopausal women. By contrast, %dBMI was found to be a predictor for %dUA, even after adjustment for WC1, %dWC, %dBPs, and %deGFR in postmenopausal women and men, although it was not significant in premenopausal women. In premenopausal women, %dBMI was not a significant predictive value for %dUA in the model in which age, UA1, BMI1, and %dBMI were used as independent variables; therefore, failure of %dBMI as a predictor for %dUA in premenopausal women may not fully be explained by the multicollinearity between %dWC and %dBMI. These findings collectively indicate that mode of association between change in BMI and change in UA differs between premenopausal and postmenopausal women.

There are several previous studies in which changes in obesity measures have been analyzed in relation to the changes in UA over a certain period of time. For example, Heyden, *et al* showed that there was a stepwise progression from decreased UA levels associated with maximum weight loss to increased levels with maximum weight gain<sup>16</sup>. In addition, Rathmann, *et al*<sup>7</sup> analyzed the data of 1249 male and 1362 female subjects aged 17–35 years from the Coronary Artery Risk Development in Young Adults (CARDIA) Study who attended a 10-year followup. They reported that changes in BMI and WC were associated with changes in UA in a statistical model adjusted for age and baseline UA levels<sup>7</sup>. In contrast, we found that %dBMI was,

but %dWC was not, significantly associated with %dUA in multiple linear regression (Table 2, models 2-5). This might be because statistical significance had been weakened after %dWC and %dBMI were simultaneously included into the statistical model; however, %dWC was not significantly associated with %dUA in women even before the adjustment for %dBMI (model 1). From our epidemiological study, we cannot determine what would have caused the different observations between the findings of Rathmann, *et al*<sup>7</sup> and our own. However, considering that circulating insulin levels may have potential to regulate serum UA levels<sup>17</sup>, the difference might derive from the difference in insulin sensitivity<sup>18,19</sup> and/or difference in the effect of obesity on insulin resistance<sup>20</sup> among various ethnicities. This possibility should be investigated in future studies. Choe, *et al* found that mean changes in BMI, but not in WC, were statistically different between subjects who had decreased or had no change in UA and those with increased UA during a 1-year followup in men who underwent health promotion screening<sup>9</sup>. They also found that changes in serum creatinine levels, but not in systolic or diastolic blood pressure, were significantly different between subjects who had decreased or unchanged UA levels and those with increased UA<sup>9</sup> — a finding that is, in one sense, in agreement with our observations.

What would be the possible underlying mechanisms that explain the difference in the mode of association between




Figure 1. Scatterplot and linear regression between waist circumference at the first visit (WC1) and uric acid at the first visit (UA1) and those between body mass index at the first visit (BMI1) and UA1 in premenopausal and postmenopausal women and in men. Serum uric acid values were not adjusted for age or other possible confounders.

%dBMI and %dUA between premenopausal and postmenopausal women? It has been reported that certain alterations in UA metabolism may occur after the menopause; menopause leads to an increase in serum UA levels<sup>21,22</sup>, and this may be in part attributed to decreased estrogen production and subsequent reduction of the fractional excretion of UA<sup>23</sup>. In addition, a recent study suggested that association between insulin resistance and serum UA levels may be greater in postmenopausal women than premenopausal women<sup>24</sup>. Whether these phenomena are related to the difference in the mode of association between %dBMI and %dUA of premenopausal and postmenopausal women remains to be investigated.

We previously showed that obesity or overweight was significantly associated with chronic kidney disease<sup>14</sup>, and that changes in obesity measures may be associated with changes in eGFR and urinary excretion of albumin<sup>25</sup>. The strength of the current study was that we demonstrate that change in BMI was positively associated with change in UA in postmenopausal women and men independent of change in eGFR. In addition, we show that mode of association between %dBMI and %dUA was different between pre-

menopausal and postmenopausal women, which may have relation with the fact that menopause causes the elevation of serum UA<sup>21,22,26</sup>. However, controlling BMI is neither unnecessary nor ineffective in keeping the metabolic measures in optimal ranges in “premenopausal” women, because weight gain may result in the reduced insulin sensitivity and aggravation of cardiovascular risk also in premenopausal women<sup>27</sup>.

Data for visceral fat volume measured by computed tomography were not available in our study. Recent reports showed that subcutaneous fat accumulation is related to impaired urinary UA excretion<sup>6</sup>, whereas visceral fat accumulation is linked closely to the overproduction of uric acid<sup>28</sup>, and that serum UA levels are increased both in individuals with subcutaneous fat obesity and in those with visceral fat obesity<sup>28</sup>. It remains to be determined whether changes of WC will lead to an increase in urinary UA excretion in our population, and whether there is a relationship between %dUA and change in visceral fat volume.

Our study has several potential limitations. First, we had no information on the extent to which modifications of lifestyle and dietary habits affected observed changes in




Figure 2. Scatterplot and linear regression between percentage change in waist circumference (%dWC) and percentage change in uric acid (%dUA), and those between percentage change in BMI (%dBMI) and %dUA in premenopausal and postmenopausal women and in men. Serum uric acid values were not adjusted for age or other possible confounders.

general/abdominal obesity, as no program to reduce weight was conducted by our institute. Second, we did not take into account participants' level of alcohol consumption or number of cigarettes smoked; both may affect serum UA levels<sup>29,30</sup>. Third, blood samples were taken from individuals in fasting condition, which may have affected their serum creatinine levels, and thus eGFR.

In summary, during a 1-year period, percentage changes in BMI (%dBMI) were associated positively with percentage changes in serum UA levels (%dUA) in postmenopausal women and men, but not in premenopausal women. This relationship was, at least in part, independent of changes in blood pressure and renal function. Weight loss may represent an effective strategy to decrease serum UA levels without use of antihyperuricemic medications, especially in postmenopausal women and men.

## REFERENCES

1. Modan M, Halkin H, Karasik A, Lusky A. Elevated serum uric acid — a facet of hyperinsulinaemia. *Diabetologia* 1987;30:713-8.
2. Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. *Arterioscler Thromb Vasc Biol* 2005;25:1038-44.
3. Ford ES, Li C, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. *Circulation* 2007;115:2526-32.
4. Gillum RF. The association of the ratio of waist to hip girth with blood pressure, serum cholesterol and serum uric acid in children and youths aged 6-17 years. *J Chronic Dis* 1987;40:413-20.
5. Kono S, Shinchi K, Imanishi K, Honjo S, Todoroki I. Behavioural and biological correlates of serum uric acid: a study of self-defence officials in Japan. *Int J Epidemiol* 1994;23:517-22.
6. Yamashita S, Matsuzawa Y, Tokunaga K, Fujioka S, Tarui S. Studies on the impaired metabolism of uric acid in obese subjects: marked reduction of renal urate excretion and its improvement by a low-calorie diet. *Int J Obes* 1986;10:255-64.
7. Rathmann W, Haastert B, Icks A, Fiani G, Roseman JM. Ten-year change in serum uric acid and its relation to changes in other metabolic risk factors in young black and white adults: the CARDIA study. *Eur J Epidemiol* 2007;22:439-45.
8. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. *Hypertension* 2003;42:474-80.
9. Choe JY, Park SH, Kim JY, Shin IH, Kim SK. Change in serum uric acid between baseline and 1-year follow-up and its associated factors in male subjects. *Clin Rheumatol* 2008;27:483-9.

Table 2. Stepwise multiple regression analysis using %dUA as the dependent variable.

	$\beta$	(95% CI)	Standardized $\beta$	p
<b>Premenopausal women</b>				
<b>Model 1</b>				
UA1	-4.21	(-5.42, -3.00)	-0.28	< 0.001
<b>Model 2</b>				
UA1	-4.21	(-5.42, -3.00)	-0.28	< 0.001
<b>Model 3</b>				
UA1	-4.21	(-5.42, -3.00)	-0.28	< 0.001
<b>Model 4</b>				
% deGFR	-0.43	(-0.53, -0.33)	-0.34	< 0.001
UA1	-3.70	(-4.84, -2.56)	-0.25	< 0.001
<b>Model 5</b>				
%deGFR	-0.43	(-0.53, -0.33)	-0.34	< 0.001
UA1	-3.70	(-4.84, -2.56)	-0.25	< 0.001
<b>Postmenopausal women</b>				
<b>Model 1</b>				
UA1	-3.09	(-4.05, -2.13)	-0.24	< 0.001
<b>Model 2</b>				
UA1	-3.04	(-4.00, -2.09)	-0.24	< 0.001
%dBMI	0.53	(0.26, 0.81)	0.14	< 0.001
<b>Model 3</b>				
UA1	-3.04	(-4.00, -2.09)	-0.24	< 0.001
%dBMI	0.53	(0.26, 0.81)	0.14	< 0.001
<b>Model 4</b>				
%deGFR	-0.33	(-0.41, -0.25)	-0.30	< 0.001
UA1	-2.83	(-3.73, -1.92)	-0.22	< 0.001
%dBMI	0.55	(0.29, 0.81)	0.15	< 0.001
<b>Model 5</b>				
%deGFR	-0.33	(-0.41, -0.25)	-0.30	< 0.001
UA1	-2.83	(-3.73, -1.92)	-0.22	< 0.001
%dBMI	0.55	(0.29, 0.81)	0.15	< 0.001
<b>Men</b>				
<b>Model 1</b>				
UA1	-2.51	(-2.90, -2.12)	-0.27	< 0.001
%dWC	0.14	(0.04, 0.25)	0.06	0.008
<b>Model 2</b>				
UA1	-2.49	(-2.88, -2.10)	-0.27	< 0.001
%dBMI	0.32	(0.17, 0.48)	0.09	< 0.001
<b>Model 3</b>				
UA1	-2.51	(-2.89, -2.12)	-0.27	< 0.001
%dBMI	0.38	(0.22, 0.54)	0.10	< 0.001
%dBPs	-0.06	(-0.10, -0.02)	-0.06	0.006
<b>Model 4</b>				
%deGFR	-0.36	(-0.40, -0.31)	-0.32	< 0.001
UA1	-2.29	(-2.66, -1.92)	-0.25	< 0.001
%dBMI	0.35	(0.21, 0.50)	0.10	< 0.001
<b>Model 5</b>				
%deGFR	-0.36	(-0.40, -0.31)	-0.32	< 0.001
UA1	-2.29	(-2.66, -1.92)	-0.25	< 0.001
%dBMI	0.35	(0.21, 0.50)	0.10	< 0.001

Model 1. Independent variables include age, UA1, WC1, and %dWC. Model 2. Independent variables include Model 1 + BMI1 and %dBMI. Model 3. Independent variables include Model 2 + %dBPs. Model 4. Independent variables include Model 2 + %deGFR. Model 5. Independent variables include Model 2 + %dBPs and %deGFR. UA: uric acid; BMI: body mass index; BPs: systolic blood pressure; eGFR: estimated glomerular filtration rate.

10. Kokubo Y, Okamura T, Yoshimasa Y, et al. Impact of metabolic syndrome components on the incidence of cardiovascular disease in a general urban Japanese population: the suita study. *Hypertens Res*. 2008;31:2027-2035.
11. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. *Am J Kidney Dis* 2009;53:982-92.
12. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. *Clin Exp Nephrol* 2007;11:41-50.
13. Ishizaka N, Ishizaka Y, Toda E, Koike K, Seki G, Nagai R, et al. Association between chronic kidney disease and carotid intima-media thickening in individuals with hypertension and impaired glucose metabolism. *Hypertens Res* 2007;30:1035-41.
14. Ishizaka N, Ishizaka Y, Toda E, Koike K, Seki G, Nagai R, et al. Association between obesity and chronic kidney disease in Japanese: differences in gender and hypertensive status? *Hypertens Res* 2007;30:1059-64.
15. Ishizaka N, Ishizaka Y, Toda E, Shimomura H, Koike K, Seki G, et al. Association between cigarette smoking and chronic kidney disease in Japanese men. *Hypertens Res* 2008;31:485-92.
16. Heyden S, Borhani NO, Tyroler HA, Schneider KA, Langford HG, Hames CG, et al. The relationship of weight change to changes in blood pressure, serum uric acid, cholesterol and glucose in the treatment of hypertension. *J Chronic Dis* 1985;38:281-8.
17. Tsunoda S, Kamide K, Minami J, Kawano Y. Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. *Am J Hypertens* 2002;15:697-701.
18. Chiu KC, Cohan P, Lee NP, Chuang LM. Insulin sensitivity differs among ethnic groups with a compensatory response in beta-cell function. *Diabetes Care* 2000;23:1353-8.
19. Torrens JI, Skurnick J, Davidov AL, Korenman SG, Santoro N, Soto-Greene M, et al. Ethnic differences in insulin sensitivity and beta-cell function in premenopausal or early perimenopausal women without diabetes: the Study of Women's Health Across the Nation (SWAN). *Diabetes Care* 2004;27:354-61.
20. Retnakaran R, Hanley AJ, Connelly PW, Sermer M, Zinman B. Ethnicity modifies the effect of obesity on insulin resistance in pregnancy: a comparison of Asian, South Asian, and Caucasian women. *J Clin Endocrinol Metab* 2006;91:93-7.
21. Wingrove CS, Walton C, Stevenson JC. The effect of menopause on serum uric acid levels in non-obese healthy women. *Metabolism* 1998;47:435-8.
22. Hak AE, Choi HK. Menopause, postmenopausal hormone use and serum uric acid levels in US women — the Third National Health and Nutrition Examination Survey. *Arthritis Res Ther* 2008;10:R116.
23. Yahyaoui R, Esteva I, Haro-Mora JJ, Almaraz MC, Mordillo S, Rojo-Martinez G, et al. Effect of long-term administration of cross-sex hormone therapy on serum and urinary uric acid in transsexual persons. *J Clin Endocrinol Metab* 2008;93:2230-3.
24. Koga M, Saito H, Mukai M, Kasayama S, Yamamoto T. Factors contributing to increased serum urate in postmenopausal Japanese females. *Climacteric* 2009;12:146-52.
25. Ishizaka Y, Ishizaka N, Tani M, Toda A, Toda E, Koike K, et al. Association between changes in obesity parameters and incidence of chronic kidney disease in Japanese individuals. *Kidney Blood Press Res* 2009;32:141-9.
26. Sumino H, Ichikawa S, Kanda T, Nakamura T, Sakamaki T. Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia. *Lancet* 1999;354:650.
27. Lofgren IE, Herron KL, West KL, Zern TL, Brownbill RA, Ilich

Table 3. Logistic regression analysis using the highest or lowest %dUA quartile as the dependent variable.

	Independent Variable			
	%dUA ≥ 7.2%		%dUA < -7.5%	
	OR (95% CI)	p	OR (95% CI)	p
<b>Premenopausal women</b>				
Model 1				
%dBMI quartile				
First			1.19 (0.73, 1.94)	0.474
2 and 3	1.00 Reference			
4	0.65 (0.42, 0.99)	0.046	1.00 Reference	
Model 2				
%dBMI quartile				
First			1.41 (0.85, 2.34)	0.181
2 and 3	1.00 Reference			
4	0.71 (0.45, 1.10)	0.126	1.00 Reference	
%deGFR	0.93 (0.91, 0.95)	< 0.001	1.06 (1.04, 1.08)	< 0.001
%dBPs	0.99 (0.97, 1.01)	0.225	1.00 (0.98, 1.02)	0.804
<b>Postmenopausal women</b>				
Model 1				
%dBMI quartile				
First			2.04 (1.37, 3.03)	< 0.001
2 and 3	1.00 Reference			
4	1.60 (1.06, 2.41)	0.025	1.00 Reference	
Model 2				
%dBMI				
First			2.04 (1.35, 3.07)	0.001
2 and 3	1.00 Reference			
4	1.72 (1.12, 2.63)	0.013	1.00 Reference	
%deGFR	0.95 (0.93, 0.97)	< 0.001	1.05 (1.03, 1.07)	< 0.001
%dBPs	0.98 (0.97, 1.00)	0.039	1.00 (0.98, 1.01)	0.684
<b>Men</b>				
Model 1				
%dBMI quartile				
First			1.35 (1.07, 1.69)	0.011
2 and 3	1.00 Reference			
4	1.38 (1.08, 1.76)	0.010	1.00 Reference	
Model 2				
%dBMI quartile				
First			1.46 (1.14, 1.86)	0.002
2 and 3	1.00 Reference			
4	1.49 (1.15, 1.92)	0.002	1.00 Reference	
%deGFR	0.94 (0.92, 0.95)	< 0.001	1.07 (1.06, 1.08)	< 0.001
%dBPs	1.00 (0.99, 1.01)	0.300	1.00 (0.99, 1.01)	0.715

Model 1. Independent variables include age, UA1, BMI1, and %dBMI quartiles. Model 2. Independent variables include Model 1 + %dBPs and %deGFR. UA: uric acid; BMI: body mass index; BPs: systolic blood pressure; eGFR: estimated glomerular filtration rate.

- JZ, et al. Weight loss favorably modifies anthropometrics and reverses the metabolic syndrome in premenopausal women. *J Am Coll Nutr* 2005;24:486-93.
28. Matsuura F, Yamashita S, Nakamura T, Nishida M, Nozaki S, Funahashi T, et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. *Metabolism* 1998;47:929-33.
29. Liberopoulos EN, Miltiados GA, Elisaf MS. Alcohol intake, serum uric acid concentrations, and risk of gout. *Lancet* 2004;364:246-7; author reply 247.
30. Lain KY, Markovic N, Ness RB, Roberts JM. Effect of smoking on uric acid and other metabolic markers throughout normal pregnancy. *J Clin Endocrinol Metab* 2005;90:5743-6.